Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer
Randomized Controlled Multicenter Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer; SenSzi (GBG80)
Sponsor: GBG Forschungs GmbH
Listed as NCT02481128, this NA trial focuses on Early-Stage Breast Carcinoma and remains completed. Sponsored by GBG Forschungs GmbH, it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Apr 2025 — Sep 2025 [monthly]
Completed NA
-
Sep 2024 — Apr 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
▶ Show 4 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Aug 2020 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GBG Forschungs GmbH
- Kliniken Essen-Mitte
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ansbach, Germany , Bad Nauheim, Germany , Bern, Switzerland , Ebersberg, Germany , Essen, Germany , Esslingen am Neckar, Germany , Frankfurt A. M., Germany , Georgsmarienhütte, Germany , Goslar, Germany , Gütersloh, Germany and 12 more locations